Novartis Lunch Symposium: Unlocking the Potential of Leqvio (inclisiran): A Masterclass with Prof Kausik Ray and Prof Stephen Nicholls
Tracks
Arrhythmia / EP
Mechanisms and Preclinical Discovery
Clinical / Surgical
Heart Failure
Imaging
Multidisciplinary
Paediatrics / Adult Congenital
Other
EHJ / HLC
ANZET
| Friday, August 2, 2024 |
| 12:35 PM - 1:35 PM |
| Meeting Room 6 |
Details
This meeting will focus on the significance of LDL-C management in clinical practice and the potential of LEQVIO to enhance current lipid-lowering strategies. In addition to highlighting the ORION data for LEQVIO, the meeting will present findings from ORION-8. It will also introduce VictORION-ASCERTAIN, a novel model of care study designed to manage high CV risk patients in the Australian primary care setting.
12:35pm - Welcome and opening
12.40pm - Targeting LDL-C - every mmol counts
12.50pm - Introducing LEQVIO (inclisiran)
1.15pm - Introducing LEQVIO (inclisiran) in clinical practice
1.25pm - Q&A
1.35pm - Closing remarks
Speaker
Prof Kausik Ray
Professor of Public Health
Imperial College London
Unlocking the potential of LEQVIO (inclisiran): A masterclass with Prof Kausik Ray and Prof Stephen Nicholls
12:35 PM - 1:35 PMBiography
Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now, Director of ICTU-Global which is an academic ARO.
He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >160,000 citations and since 2018 has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.
Prof Stephen Nicholls
Director
Monash Healh / Monash University
Unlocking the potential of LEQVIO (inclisiran): A masterclass with Prof Kausik Ray and Prof Stephen Nicholls
12:35 PM - 1:35 PMBiography
MBBS, Ph.D., FRACP, FACC, FESC, FAHA, FCSANZ, FAHMS
Director of Victorian Heart Hospital, MonashHeart & ICU, Monash Health Director of Victorian Heart Institute, Monash University Professor of Cardiology, Monash University Professor Steve Nicholls is the inaugural Director of the Victorian Heart Institute and a Professor of Cardiology at Monash University. He is the inaugural Director of the Victorian Heart Hospital which opened in February 2023.
Steve is a preventive cardiologist. His clinical interest is focused on identifying those at risk of heart disease earlier, and more effectively, and preventing catastrophic cardiovascular events from occurring. He is committed to solutions which improve equity across risk and management, focusing on women’s heart health and other under-served populations. His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large-scale clinical trials of new therapies designed to reduce the risk of heart disease. He is Chair of the Asia Pacific Cardiometabolic Consortium, President of the Cardiac Society of Australia and New Zealand and a Fellow of the Australian Academy of Health and Medical Sciences.
Director of Victorian Heart Hospital, MonashHeart & ICU, Monash Health Director of Victorian Heart Institute, Monash University Professor of Cardiology, Monash University Professor Steve Nicholls is the inaugural Director of the Victorian Heart Institute and a Professor of Cardiology at Monash University. He is the inaugural Director of the Victorian Heart Hospital which opened in February 2023.
Steve is a preventive cardiologist. His clinical interest is focused on identifying those at risk of heart disease earlier, and more effectively, and preventing catastrophic cardiovascular events from occurring. He is committed to solutions which improve equity across risk and management, focusing on women’s heart health and other under-served populations. His work spans the translational spectrum from the lab bench to the bedside, with a focus on understanding the factors that promote plaque formation, novel vascular imaging and leadership of large-scale clinical trials of new therapies designed to reduce the risk of heart disease. He is Chair of the Asia Pacific Cardiometabolic Consortium, President of the Cardiac Society of Australia and New Zealand and a Fellow of the Australian Academy of Health and Medical Sciences.
